Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipelin...
Phio Pharmaceuticals Corp. (PHIO)
Last phio pharmaceuticals corp. earnings: 11/12 07:45 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
King of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL ® gene silencing technology to eliminate cancer. Phio announced today that a podium presentation addressing its lead product candidate, PH-762, will be given in the American Academy of Dermatology's Late-Breaking Research Session S034 on March 28, 2026 in Denver, Colorado. The presentation, entitled "PD-1 Directed Intratumoral Immunotherapy: Results of an Escalating Dose Study of INTASYL PH-762 for Cutaneous Carcinomas will highlight results of Phio's Phase 1b clinical study (NCT 06014086) which evaluated the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. "The clinical study results are encouraging and firmly guide Phio to continued clinical development of this immuno-on
Show less
Read more
Impact Snapshot
Event Time:
PHIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHIO alerts
High impacting Phio Pharmaceuticals Corp. news events
Weekly update
A roundup of the hottest topics
PHIO
News
- Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT [Yahoo! Finance]Yahoo! Finance
- Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTGlobeNewswire
- Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTGlobeNewswire
- Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company [Yahoo! Finance]Yahoo! Finance
- Phio Pharmaceuticals (NASDAQ:PHIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
PHIO
Analyst Actions
- 2/10/26 - HC Wainwright
PHIO
Sec Filings
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- 2/18/26 - Form 8-K
- PHIO's page on the SEC website